Dataset Information

Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of an high emetic risk chemotherapy.

ABSTRACT: Interventions: Group A: * 1st course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 3rd day. * 2nd course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 13.2mg i.v. on 3rd day. Group B: * 1st course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 13.2mg i.v. on 3rd day. * 2nd course: Palonosetron 0.75mg i.v. on 1st day+Aprepitant 150mg i.v. on 1st day+Dexamethasone 9.9mg i.v. on 1st day, 6.6mg i.v. on 2nd day and 3rd day. Primary outcome(s): * Blood concentration of dexamethasone Study Design: Cross-over Randomized

DISEASE(S): Inoperable Advanced/recurrence Gastric Cancer Or Esophageal Cancer Or Colorectal Cancer

PROVIDER: 2629132 | ecrin-mdr-crc |

REPOSITORIES: ECRIN MDR

ACCESS DATA

Similar Datasets

Project description:To find out the binding partners of EhRacM, crosslinking and coimmunoprecipitation were performed. Then, eluted samples were submitted to Mass Spectrometry and Proteomics Core Facility, Johns Hopkins University School of Medicine and analyzed by mass spctrometry (shotgun proteomics). The coimmunoprecipitation and following analysis were conducted three times.You can find the data of HA-EhRacM (1st) from "2022_7_32_54_PM_FileSize_500998639_Byte_F010303.mzid.gz", "2022_7_32_54_PM_FileSize_500998639_Byte_F010303.mzid_2022_7_32_54_PM_File_Size__500998639__Byte__F010303.MGF", "RO-CS-LE_220912_NozakiT_MS_Rac16_WT.mzML", and "RO-CS-LE_220912_NozakiT_MS_Rac16_WT.RAW". You can find the data of pEhExHA (mock) (1st) from "2022_5_02_01_AM_FileSize_662636563_Byte_F010297.mzid.gz", "2022_5_02_01_AM_FileSize_662636563_Byte_F010297.mzid_2022_5_02_01_AM_File_Size__662636563__Byte__F010297.MGF", "RO-CS-LE_220912_NozakiT_MS_pEhExHA.mzML", and "RO-CS-LE_220912_NozakiT_MS_pEhExHA.RAW".You can find the data of HA-EhRacM (2nd) from "2022_7_35_46_AM_FileSize_794949236_Byte_F009769.mzid.gz", "2022_7_35_46_AM_FileSize_794949236_Byte_F009769.mzid_2022_7_35_46_AM_File_Size__794949236__Byte__F009769.MGF", "JS-QE-CS_221108_NozakiT_MS_S1_RA.msf", "JS-QE-CS_221108_NozakiT_MS_S1_RA.RAW", "JS-QE-CS_221108_NozakiT_MS_S1_RA.mzML". You can find the data of pEhExHA (mock) (2nd) from "2022_2_58_28_AM_FileSize_846222756_Byte_F009771.mzid.gz", "2022_2_58_28_AM_FileSize_846222756_Byte_F009771.mzid_2022_2_58_28_AM_File_Size__846222756__Byte__F009771.MGF", "JS-QE-CS_221108_NozakiT_MS_S4_RA.msf", "JS-QE-CS_221108_NozakiT_MS_S4_RA.RAW", and "JS-QE-CS_221108_NozakiT_MS_S4_RA.mzML". You can find the data of HA-EhRacM (3rd) from "2023_12_15_11_AM_FileSize_1380630557_Byte_F012916.mzid.gz", "2023_12_15_11_AM_FileSize_1380630557_Byte_F012916.mzid_2023_12_15_11_AM_File_Size__1380630557__Byte__F012916.MGF", "JS-E480-CS_230518_NozakiT_MS_S1_DDA_10pct.msf", "JS-E480-CS_230518_NozakiT_MS_S1_DDA_10pct.mzML", and "JS-E480-CS_230518_NozakiT_MS_S1_DDA_10pct.RAW". You can find the data of pEhExHA (mock) (3rd) from "2023_6_35_51_PM_FileSize_1732075728_Byte_F012915.mzid.gz", "2023_6_35_51_PM_FileSize_1732075728_Byte_F012915.mzid_2023_6_35_51_PM_File_Size__1732075728__Byte__F012915.MGF", "JS-E480-CS_230518_NozakiT_MS_S4_DDA_10pct.msf", "JS-E480-CS_230518_NozakiT_MS_S4_DDA_10pct.mzML", and "JS-E480-CS_230518_NozakiT_MS_S4_DDA_10pct.RAW".

Dataset Information

Examination about the pharmacokinetics of the dexamethasone under the Fosaprepitant medication to the nausea and vomiting of an high emetic risk chemotherapy.

Similar Datasets

OmicsDI is part of the ELIXIR infrastructure

Tweets